If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 241 - 250 of 296
A Phase I Multicohort Trial of Zamtocabtagene Autoleucel (Zamto-Cel) in Subjects with Severe Refractory Autoimmune Diseases
Objective
US Zamto-cel Autoimmune Diseases
Protocol No
RHEU-MILTENYI-M-2024-423
Categories
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Single, Site, Pragmatic Pilot Study
Objective
Impact of Glucagon-like Peptide on Disease Outcomes
Protocol No
RHEU-IIT-SINGLA-GLP-1
Categories
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Phnegative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly-Diagnosed Older Adults or Adults With Relapsed or Refractory Disease and Feasibility Study of Ponatinib Wi
Objective
A Phase 2 Study of Inotuzamab Ozogamicin in Patients with ALL in Newly Diagnosed Adults
Protocol No
ALLIANCE-A041703
Categories
An Open-Label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens in Patients with Gynecological Cancers (BELLA)
Objective
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Protocol No
CORCEPT-CORT125134-557-BELLA
Categories
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse
Objective
Study of bispecific antibody therapy for post-BCMA therapy relapse
Protocol No
IIT-DHAKAL-RECLAIM
Categories
Phase II Study of Zanzalintinib in Men with Aggressive Variant Prostate Cancer (NAPOLEON study)
Objective
Phase II Study of Zanzalintinib in Men with Aggressive Variant Prostate Cancer
Protocol No
HCRN-GU23-655-NAPOLEON
Categories
BAF_FRontier-01, A First-in-Human, Phase 1a/1b Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-Cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody, in Adult Participants with Previously Treated
Objective
A Phase 1a/1b Study of LY4152199 in Patients with Previously Treated B-cell Malignancies
Protocol No
LILLY-J6N-MC-JUCA
Categories
A Phase 1, Open-Label, Multicenter, First-in-Human Trial of DS3610A in Participants with Advanced Solid Tumors
Objective
A Phase 1 Study of DS3610A in participants with advance solid tumor cancer.
Protocol No
DAIICHI-DS3610-071
Categories
A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-Clinical Practice Patient Population With HR+ HER2- Early Breast Cancer
Objective
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy on invasive breast cancer-free survival, in a close to clinical practice patient population with HR-positive, HER2-negative, early breast cancer.
Protocol No
NOVARTIS-CLEE011O12001-WIDER
Categories
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Patients With Endocrine-Resistant Hormone
Objective
A study to evaluate the efficacy and safety of triplet combination of inavolisib plus ribociclib and fulvestrant versus placebo plus ribociclib and fulvestrant in the first-line setting in participants with endocrine-therapy-resistant hormone receptor positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Protocol No
HOFFMAN-LAROCHE-CO46274
Categories